LB PHARMACEUTICALS INC
LBRX · XNASCIK 1691082fmd_1RYMKAN2WAQT488RK2Z0VHQFN5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 11 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 51 | 17 |
| Total operating expenses | 65 | 30 |
| Interest and investment income | 2 | 4 |
| Other non-operating income (expense) | 2 | 5 |
| Income before taxes | (63) | (25) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (63) | (25) |
| Net income | (63) | (25) |
| Net income to common shareholders | (0) | (0) |